Investor presentation

February 19, 2025

Important information

Forward-looking statements and other important information

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*), future restructuring and acquisition related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward-looking statements made about our strategy, estimates of sales growth, future Adjusted EBITA*), future containing words such as "anticipates", "espects", "espects", "espects", "will", "will", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include but are not limited to: Philips' ability to gain leadership in health informatics and artificial intelligence in response to developments in the health technology industry; Philips' ability to keep pace with the changing health technology environment; macroeconomic and geopolitical changes, including protectionism measures such as announced and proposed tariffs and retaliatory trade measures in response thereto; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights; ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breach of cybersecurity; challenges in simplifying our organization and our ways of working; the resilience of our supply chain; attracting and retaining personnel; challenges in driving operational excellence and speed in bringing innovations to market; compliance with business conduct rules and regulations including privacy and upcoming ESG disclosure and due diligence requirements; treasury and financing risks; tax risks and reliability of internal controls. As a result, Philips' actual future results may differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2023. Reference is also made to section Risk management in the Philips semi-annual report 2024.

Third-party market share data

Statements regarding market share contained in this document, including those regarding Philips' competitive position, are based on outside sources such as specialized research institutes, industry and dealer panels, in combination with management estimates. Where full year information regarding 2024 is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This slide deck contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation

Use of non-IFRS Information

In presenting and discussing the Philips Group's financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2023.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2023. Prior-period amounts have been reclassified to conform to the current-period presentation; this includes immaterial organizational changes. Effective Q1 2024, Philips has revised the order intake policy to reflect the full contract value for software contracts that start generating revenue within an 18-month horizon, instead of only the next 18-months-to-revenue horizon. This change has been implemented to better align with the specific business model of our software businesses, simplify the order intake process, and better align with peers. Prior-period comparable order intake percentages have been restated accordingly. This revision has not resulted in any material changes to the order intake percentages for the periods presented. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares in the second quarter of 2024 in connection with the 2023 share dividend.

Company overview

Creating value with sustainable impact

Path to value creation



© Koninklijke Philips N.V.

Our purpose: To improve people's health and well-being through meaningful innovation.

Our vision: Better care for more people.



Philips at a glance

EUR 18.0bn in sales; 11.5% Adjusted EBITA margin¹

~70% sales from #1 or #2 positions ~40% of sales from recurring revenues

~9% of sales invested in R&D

Leader in ESG as highest ranking HealthTech company³

Global sales footprint¹ North America 43% Western Europe 22% Other mature geographies 8% Growth geographies² 27%

1.2024 full-year | 2. Growth geographies consist of all geographies excluding USA, Canada, Western Europe, Australia, New Zealand, South Korea, Japan and Israel | 3. In Dow Jones Sustainability Index World

Well-positioned to capture growing and attractive markets, enabling better care for more people through sustainable innovation

Addressable market¹

EUR ~90 billion in 2025

Mid-single digit 2022-2025 CAGR

Structural and increasing gap between demand and supply of care

- Aging population and more patients
- Growing chronic and complex diseases
- Increasing spend on self-care and personal health
- Staff shortages and rising costs
- Expanding access to healthcare

Fundamentally attractive market whilst short term dynamics differ per region

North America

- Hospital productivity needs and consolidation
- Potential policy
 changes in 2025
- Stable consumer confidence

Europe

- Hospital productivity needs; digitization of health care
- Pockets of growth in north and south Europe
- Stable consumer spending

 Fundamentally attractive due to strong underlying health care demand

Greater China

- Impact of anti-corruption and national renewal program
- Low consumer confidence

Rest of World

- Opportunities driven by government investment and digitization
- Lower growth in mature geographies focusing on productivity
- Strong consumer opportunities

Our businesses

Diagnosis & Treatment



EUR 8.8 billion

11.6% adjusted EBITA margin

Connected Care



EUR 5.1 billion

9.6% adjusted EBITA margin

Personal Health



EUR 3.6 billion sales

16.7% adjusted EBITA margin

We leverage platforms for personal health, monitoring, imaging and interventional to serve our customers across care settings



Enabled and connected by Enterprise Informatics and services

Diagnosis & Treatment - advancing outcomes for more patients and hospital productivity with precise and predictive imaging



Enabled by industry leading Enterprise Informatics #1 in PACS¹ and inter-operability

Diagnosis & Treatment – a global leader uniquely integrating systems, software, and devices in one interventional platform

Image-Guided Therapy Systems





Image-Guided Therapy Devices





#1 Globally

#1 Cath lab systems#1 Interventional cardiology#2 Interventional neurovascular

#1 Globally

#2 Coronary devices#1 Peripheral vascular devices#1 Lead management#1 3D Intracardiac echography

Market leading installed base

PHILIPS

Connected Care – global leader in hospital and ambulatory Monitoring, largest vendor-agnostic Enterprise Informatics

Monitoring



#1 Globally

in Hospital and Ambulatory

Enterprise Informatics



#1 PACS¹, interoperability

Sleep & Respiratory Care



#2 Globally

Personal Health - strong leadership across businesses, supported by innovation and a trusted brand

Personal Care



#1 Electric shaving & grooming #1 Intense Pulsed Light

Oral Healthcare



#2 Globally #1 US Rechargeable power toothbrush

Mother & Childcare



#2 Bottle feeding#1 Pregnancy engagement app

ESG integrated in our purpose and strategy

Leader in ESG as highest ranking HealthTech company¹

Environment



- Maintain carbon neutrality² and Science Based Targets for scope 1-3
- Innovation in line with Eco-design requirements

Social



- Improve health and well-being of 2.5bn people, 400m underserved
- Be best place to work, purpose driven, living diversity and inclusion

Governance



- Maintain highest standards of ethics and governance
- Transparent plans, activities, results and contributions

We are deploying our new culture of impact with care, building on the right team and Healthtech capabilities



The right team and capabilities

70%

Renewal of Executive Committee

75%

Executive hires with Healthtech and clinical background

78%

Employee engagement score

Experienced and passionate executive team



Company overview

Creating value with sustainable impact

Path to value creation



Our plan

Strategy

Innovation

Execution

Focused growth and value creation

People and patient-centric innovation, business-led, at scale

1. Patient Safety and Quality

2. Reliable end-to-end supply chain

3. Simplified operating model

Supported by a culture of impact with care and HealthTech talent and capabilities

PHILIPS

Focused growth and value creation strategy

70% of revenue, industry leading margins	Accelerating growth in attractive leadership segments	30% of revenue, margin upside
Image-Guided Therapy	Ultrasound	Enterprise InformaticsScale to unlock insights and deliver profitable growth
		Diagnostic Imaging Enhance operational excellence, focus on customer productivity
Monitoring	Personal Health	Sleep & Respiratory Care Restore business profitability and position

PHILIPS

Largest vendor-agnostic Enterprise Informatics business

EUR	1.2 billion sales ~ 2x Philips gr	rowth
Imaging informatics	Clinical integration	Telecare
Diagnosing patients by reviewing images	Integrating and analyzing data from >1,200 medical devices	Enable remote care delivery
#1 Radiology #1 Cardio #3 Pathology	#1 Medical device integration (US)	#1 eICU #1 Critical care EMR

Creating value for stakeholders through high-impact innovation

€1.7bn >9% of sales in 2024, industry leading

~50% of sales

from new and upgraded products launched in last 3 years >50% of R&D workforce on software, data & Al

Innovating sustainably with quality as highest priority



People and patient-centric

Ecosystem with clinical and technology partnerships

Curr

Business-led



Businesses are accountable to deliver innovation from creation to delivery

Focused, standard-setting innovation with higher return



Innovation is deeply clinically embedded through global partnerships



Businesses are accountable to deliver innovation from creation to delivery



PHILIPS

Scalable innovations setting the standard across segments of care



- Helium-free
- Installable everywhere
- Al-enabled
- >1400 systems installed



- One more patient a day
- Industry leader cardiac care, extending to brain
- 5 million procedures a year on Azurion system

Patient Information Center iX



- Monitoring ecosystems across all acuity settings
- Up-to-minute data for 1,600 patients
- 1 in 2 hospitals use this PIC iX monitor in the US

OneBlade



- New hybrid shaving category
- 90% market share
- 100+ million blades & 50+ million handles sold

Ñ.

AI-driven, industry-leading innovations launched in 2024



PHILIPS



Execution as key value driver



Patient safety and quality as highest priority



Reliable end-to-end supply chain



Simplified operating model

We have made solid progress on our execution priorities



Patient safety and quality embedded in businesses, innovation and culture



End-to-end supply chain delivering better lead times and service



Enhancing patient safety and quality	Supply chain set-up	Business in lead – clear accountability, lean, agile
Innovation, quality design, integrated process	Product simplification	Right team, HealthTech capabilities
Improving compliance	Supplier reliability	Deploying culture of impact with care

PHILIPS

Company overview

Creating value with sustainable impact

Path to value creation



© Koninklijke Philips N.V.

Continued solid execution of the three-year plan

	2023-2025 plan As provided Jan 30, 2023	2023-2024 plan-to-date	
Comparable Sales Growth	From low-to-mid single digits	~3.5% CAGR	Driven by solid growth ex-China
Adj. EBITA margin ¹	From high single digits to low teens	+410 bps	Operational improvements, productivity savings and pricing
Free Cash Flow ²	EUR 3.0-3.6 billion ³	EUR 2.5 billion	Higher earnings, working capital management, financial discipline
Net Debt/ Adj. EBITDA	1.5x	1.8x	Significant deleveraging

1. Excluding restructuring costs, acquisition-related charges and other one-time charges and gains | 2. Cumulative in the period | 3. Excluding payments and receipts related to the Respironics litigation in the US

30

Expect to improve performance, grow sales and orders within a challenging macro environment and expand margin

FY 2025 outlook

Comparable sales growth 1-3%	 All business segments growing within the range Back end loaded year with China expected to decline mid-to-high single digit due to double digit decline in Q1 and Q2

Adj. EBITA margin	Improvement across business segments, with additional productivity and innovation
Increase 30-80bps to 11.8-12.3%	 Accelerating growth in attractive leadership segments, capturing value upside in businesses with lower margins

Free Cash Flow

Lower end of EUR 1.4-1.6 billion range

- Before payment of the USD 1.1 billion cash-out relating to the US medical monitoring and personal injury settlements
- Net of these settlements, free cash flow will be EUR 0.4-0.6 billion.

Productivity initiatives¹ to deliver EUR 2.5 billion in the 2023-2025 period


Productivity initiatives savings¹

In millions of EUR unless otherwise stated		2023-2025 target
Operating model	 Simplified operating model R&D prioritization, reduction of Corporate Research End-to-end supply chain, simplifying planning, and eliminating duplications 	1,050-1,150
Procurement	 Bill-of-material savings via redesign, value analysis, engineering Reductions in warehousing, transportation and consulting 	650-700
Other productivity	 Manufacturing footprint optimization and service productivity R&D platform simplification and footprint optimization GBS and hyper-automation Sleep & Respiratory Care rightsizing 	700-750

~2,500

Margin increase from productivity, pricing and supply chain improvements – cumulative drivers 2023-2025

Adj. EBITA margin¹



Balanced capital allocation focusing on organic growth, margin improvement and cash

1	Organic growth	 Main premise of our value creation 	Shareholder	
2	Dividend stability	Pay-out of 40-50% of net recurring incomeContinued, stable dividend policy	returns	
3	M&A	 Disciplined, bolt-on M&A in core areas 	Maintain strong investment grade	
4	Share buy-backs	 In April 2024, completed EUR 1.5 billion program announced in July 2021 Continuing to evaluate periodically 	rating	

PHILIPS

2023-2025

Execute our plan, drive profitable growth

Making solid progress on execution:

- Patient Safety & Quality as first priority
- Reliable supply chain
- Simplification of operating model

Within a more challenging macro environment

Creating value with sustainable impact

2025+

Deliver on full potential of our segments

Focused growth and value creation strategy

Delivering people and patientcentric innovation at scale

Execution as key value driver

Delivered by Healthtech talent and culture of impact with care

Better care for more people


PHILIPS

PHILPS


Historical financial performance summary

Key data in millions of EUR unless otherwise stated	2022	2023	2024
Sales	17,827	18,169	18,021
Comparable sales growth	(3)%	6%	1%
Income from operations	(1,529)	(115)	529
Financial expenses, net	(200)	(314)	(282)
Investments in associates, net of income taxes	(2)	(98)	(124)
Income tax expense	113	73	(963)
Income from continuing operations	(1,618)	(454)	(840)
Discontinued operations, net of income taxes	13	(10)	142
Net income	(1,605)	(463)	(698)
Adjusted EBITA ¹	1,318	1,921	2,077
as a % of sales	7.4%	10.6%	11.5%
Adjusted income from continuing operations attributable to shareholders ² per common share (in EUR) - diluted	0.92	1.25	1.38


Balanced capital allocation policy




Organic Return on Invested Capital^{1,2}



Mergers & acquisitions (in billions of EUR unless otherwise stated)



Share repurchase (in billions of EUR unless otherwise stated)



1. Organic ROIC excludes acquisitions over a five years period and other items defined as material and of the same nature as the items excluded from Adjusted EBITA such as pension settlements, significant tax charges and benefits, and one-time legal and other provisions; ROIC % = LTM EBIAT/ average NOC over the last 5 quarters; 2. Organic ROIC 2019 and 2021 restated to reflect discontinued operations; 3. Organic ROIC in 2019 includes value adjustments of capitalized development costs and

the impact of IFRS 16 lease accounting standard